Sagban, T., Jaccob, A., Yaqoub, A., Khadim, H. (2023). Systemic Adverse Effects of Topical Clobetasol and Counterfeit Cosmetic Products on Iraqi Women. Alustath, 20(Supplementary Issue 1), 201-209. doi: 10.33899/iphr.2023.143457.1061
Teeba H. Sagban; Ausama Ayob Jaccob; Abdulla Ayob Yaqoub; Huda Khadim. "Systemic Adverse Effects of Topical Clobetasol and Counterfeit Cosmetic Products on Iraqi Women". Alustath, 20, Supplementary Issue 1, 2023, 201-209. doi: 10.33899/iphr.2023.143457.1061
Sagban, T., Jaccob, A., Yaqoub, A., Khadim, H. (2023). 'Systemic Adverse Effects of Topical Clobetasol and Counterfeit Cosmetic Products on Iraqi Women', Alustath, 20(Supplementary Issue 1), pp. 201-209. doi: 10.33899/iphr.2023.143457.1061
Sagban, T., Jaccob, A., Yaqoub, A., Khadim, H. Systemic Adverse Effects of Topical Clobetasol and Counterfeit Cosmetic Products on Iraqi Women. Alustath, 2023; 20(Supplementary Issue 1): 201-209. doi: 10.33899/iphr.2023.143457.1061

Systemic Adverse Effects of Topical Clobetasol and Counterfeit Cosmetic Products on Iraqi Women

Iraqi Journal of Pharmacy
Volume 20, Supplementary Issue 1, December 2023, Pages 201-209    PDF (779.89 K)
Document Type: Research Paper
DOI: 10.33899/iphr.2023.143457.1061
Authors
Teeba H. Sagban1; Ausama Ayob Jaccob* 2; Abdulla Ayob Yaqoub3; Huda Khadim4
1Ministry of Health, Maysan Health Department, Al-Kahla Hospital, Maysan, Iraq
2Department of Pharmacology and Toxicology, College of Pharmacy, Basrah University, Basrah, Iraq
3Department of Dermatology, Abu Al-Khaseeb Hospital, Basrah, Iraq
4Ministry of Health, Maysan Health Department, Al-Sader Hospital, Maysan, Iraq
Abstract
Background: Topical corticosteroids (TCs) are widely used for dermatologic diseases. Unfortunately, there exists many adverse effects (local and systemic). These adverse effects are comparable to those observed when glucocorticoids are administered systemically, but they are typically less severe. Aim: To assess the systemic adverse effects of topical clobetasol (TCL) and counterfeit cosmetic products (CCP) on Iraqi women. Methods and patients: This was a cross-sectional observational study; carried out from October 2022 to March 2023. Patients visited the outpatient clinic of the Department Dermatology and Venereology in Abu-al Khasib Hospital in Basra City, Iraq. Patients may be categorized into two distinct groups: the first group of subjects utilized TCL (n=31), while the second group consisted of patients with CCP (n=32), and the remaining participants were designated as the control group (n=35). A specialized dermatologist conducted a clinical examination to make a diagnosis. A questionnaire was collected, and blood samples were obtained for laboratory investigations. Results: TCs suppressed vitamin D (Vit-D), interlukin-6 (IL-6), testosterone, and estrogen and reduced cortisol concentrations significantly. TCs elevated red blood cells (RBC), neutrophils percent (NEU%), and hemoglobin (HB) levels significantly and prolong bleeding time. While not affecting WBCs, PLT, MPV, MCH, MCV, ACTH, or insulin levels, with decreased in HCT, MCHC, Eos%, and Lym% for all groups in comparison to control group. Conclusion: Topical corticosteroids are extensively used, mostly for the treatment of dermatological conditions. However, they can be misused for their cosmetic effects as fairness creams. TCs misuse is a big problem in Iraq, resulting in massive skin effects and systemic deterioration, such as hematological and hormonal effects. Nevertheless, the general population remains ignorant of the systemic adverse effects. Educational activities targeting the public are suggested to address the systemic deterioration.
Keywords
Adverse effect; Clobetasol; Counterfeit cosmetic products; Topical corticosteroids
References
  1. Saraswat A. Ethical use of topical corticosteroids. A Treatise on Topical Corticosteroids in Dermatology: Use, Misuse and Abuse.2018; 73-79.
  2. Horn E, Domm S, Katz H, Lebwohl M, Mrowietz U, Kragballe K. International Psoriasis Council. Topical corticosteroids in psoriasis: strategies for improving safety. Journal of the European Academy of Dermatology and Venereology. 2010; 24(2), 119-124.
  3. Devaraj N, Aneesa A, Abdul Hadi A, Shaira N . Topical corticosteroids in clinical practice. Med J Malaysia. 2019;74(2):187-9.
  4. Humbert P, Guichard A. The topical corticosteroid classification called into question: towards a new approach. Experimental Dermatology. 2015;24(5):393-395.
  5. Güven A, Gülümser Ö, Özgen T. Cushing's syndrome and adrenocortical insufficiency caused by topical steroids: misuse or abuse?. Journal of Pediatric Endocrinology and Metabolism. 2007;20(11):1173-1182.
  6. Allenby C, Main R, Marsden R, Sparkes C. Effect on adrenal function of topically applied clobetasol propionate (Dermovate). Br Med J.1975; 4(5997): 619-621.‏
  7. Ference J, Last Choosing topical corticosteroids. American family physician. 2009; 79(2): 135-140
  8. Olsen E, Cornell R.. Topical clobetasol-17-propionate: review of its clinical efficacy and safety. Journal of the American Academy of Dermatology. 1986;15(2):246-255.‏
  9. Mahe A, Ly F, Aymard G, Dangou J. Skin diseases associated with the cosmetic use of bleaching products in women from Dakar. Senegal. British journal of dermatology.2003; 148(3): 493-500.‏
  10. Rathi SK, D’Souza P. Abuse of topical corticosteroid as cosmetic cream: a social background of steroid dermatitis. A Treatise on Topical Corticosteroids in Dermatology: Use, Misuse and Abuse. 2018;129-35.
  11. Giaccone V, Polizzotto G, Macaluso A, Cammilleri G, Ferrantelli V. Determination of ten corticosteroids in illegal cosmetic products by a simple, rapid, and high-performance LC-MS/MS method. International Journal of Analytical Chemistry.2017.‏
  12. Aljunaiyeh H, Naif A, Kadhim K. Non-prescription skin lightening preparations; their use & hazards in Iraq.  J. Pharm. Res. Allied. Sci.2018; 7(2): 209-17.‏
  13. Alghamdi K. The use of topical bleaching agents among women: a cross‐sectional study of knowledge, attitude and practices. Journal of the European Academy of Dermatology and Venereology.2010;24(10): 1214-1219.‏
  14. Jaccob A, Yaqoub A, Rahmani M. Impact of abuse of topical corticosteroids and counterfeit cosmetic products for the face: prospective demographic study in basrah city, Iraq. Current Drug Safety.2020;15(1): 25-31.‏
  15. Dhar S, Seth J, Parikh D. Systemic side-effects of topical corticosteroids. Indian journal of dermatology.2014;59(5): 460.‏
  16. Varshney I, Amin S, Adil M, Mohtashim M, Bansal R, Khan H. Topical Corticosteroid Abuse–Risk Factors and Consequences. Indian Journal of Clinical Dermatology| Volume.2019;2(03).‏
  17. Bhatti R, Flynn M. Adrenal insufficiency secondary to inappropriate oral administration of topical exogenous steroids presenting with hypercalcaemia. Case Reports. 2012;‏
  18. Hwang J, Weiss R. Steroid‐induced diabetes: a clinical and molecular approach to understanding and treatment. Diabetes/metabolism research and reviews.2014; 30(2): 96-102.‏
  19. Poetker D, Reh D. A comprehensive review of the adverse effects of systemic corticosteroids. Otolaryngologic Clinics of North America.2012;43(4): 753-768.‏
  20. Alessi J, de Oliveira G, Schaan B, Telo G. Dexamethasone in the era of COVID-19: friend or foe? An essay on the effects of dexamethasone and the potential risks of its inadvertent use in patients with diabetes. Diabetology & Metabolic Syndrome.2020;12:1-11.‏
  21. Stout A, Friedly J, Standaert C. Systemic absorption and side effects of locally injected glucocorticoids. PM&R.2019;11(4): 409-419.‏
  22. Whirledge S, Cidlowski J. Glucocorticoids, stress, and fertility. Minerva endocrinologica.2010; 35(2); 109.‏
  23. Danisova A, Seböková E, Kolena J. Effect of corticosteroids on estradiol and testosterone secretion by granulosa cells in culture. Experimental and clinical endocrinology.1987; 89(2): 165-173.
  24. ‏Yahi D, Ojo N, Mshelia G.  Effects of dexamethasone on progesterone and estrogen profiles and uterine progesterone receptor localization during pregnancy in Sahel goat in Semi-Arid region. Journal of animal science and technology.2017; 59(1): 1-7.‏
  25. De Nijs R. Glucocorticoid-induced osteoporosis: a review on pathophysiology and treatment options. Minerva medica.2008;99(1): 23.‏
  26. Canalis E, Giustina A, Bilezikian,J. Mechanisms of anabolic therapies for osteoporosis. New England Journal of Medicine.2017; 357(9):905-916.‏
  27. Ballin A, Waisbourd‐Zinman O, Saab H, Yacobovich J, Zoldan M, Barzilai‐Birenbaum S, Tamary H. Steroid therapy may be effective in augmenting hemoglobin levels during hemolytic crises in children with hereditary spherocytosis. Pediatric blood & cancer.2011;57(2): 303-305.
  28. ‏McKay L, Cidlowski J. Physiologic and pharmacologic effects of corticosteroids. Holland-Frei cancer medicine.2003; 6.‏
  29. Starch-Jensen, T, Deluiz D, Bruun N, Tinoco E. Maxillary sinus floor augmentation with autogenous bone graft alone compared with alternate grafting materials: a systematic review and meta-analysis focusing on histomorphometric outcome. Journal of Oral & Maxillofacial Research.2020;11(3).
  30. ‏Macečková Z, Kubíčková A, De Sanctis J, Hajdúch M. Effect of glucocorticosteroids in Diamond-Blackfan anaemia: maybe not as elusive as it seems. International Journal of Molecular Sciences.2022;23(3): 1886.‏
  31. Zhang Q, Shan K, Raza A, Manda N, Nace T. A rare case report and literature review of anabolic-androgenic steroids (AAS)-induced acute myocardial infarction. 2020;12(5).‏
  32. Pasternak Y, Yarden-Bilavsky H, Kodman Y, Zoldan M, Tamary H, Ashkenazi S. Inhaled corticosteroids increase blood neutrophil count by decreasing the expression of neutrophil adhesion molecules Mac-1 and L-selectin. The American journal of emergency medicine.2016;34(10): 1977-1981.‏
  33. Barnes P. New molecular targets for the treatment of neutrophilic diseases. Journal of Allergy and Clinical Immunology.2007;119(5): 1055-1062.‏
  34. Nguyen L, Lim S, Oates T, Chung K. Increase in airway neutrophils after oral but not inhaled corticosteroid therapy in mild asthma. Respiratory medicine.2005;99(2): 200-207.‏
  35. Royer B, Gruson B., Roszkiewicz F, Al Khedr A., Colson A., Marolleau J. Methylprednisolone-induced immune thrombocytopenia. Blood, The Journal of the American Society of Hematology.2010; 115(26): 5431-5432.
  36. ‏Vogel T, Verreault,R. Letter to Editor: Thrombocytopenia Following Steroid Therapy In An 83-year-old Woman. The Journals of Gerontology Series A: Biological Sciences and Medical Sciences.2002.57(8): M519-M520.‏
  37. Taguchi R, Tsuchihashi K., Okumura Y, Nakano M, Yoshihiro T, Ohmura H, Baba, E. Thrombocytopenia caused by dexamethasone in a patient with colorectal cancer. Internal Medicine.2020;59(20): 2571-2575.‏
  38. Praituan W, Rojnuckarin P. Faster platelet recovery by high-dose dexamethasone compared with standard-dose prednisolone in adult immune thrombocytopenia: a prospective randomized trial. Journal of Thrombosis and Haemostasis.2009; 7(6):1036-1038.‏
  39. Gras M, Verrecchia F, Uitto J, Mauviel A. Downregulation of human type VII collagen (COL7A1) promoter activity by dexamethasone: Identification of a glucocorticoid receptor binding region. Experimental dermatology.2001;10(1): 28-34.‏
  40. Whalen K. Lippincott® illustrated reviews: pharmacology. Wolters kluwer india Pvt Ltd.‏;2018.
  41. Al Saleh Y., Beshyah S, Hussein W, Almadani A, Hassoun A, Al Mamari A, Al-Daghri N. Diagnosis and management of vitamin D deficiency in the Gulf Cooperative Council (GCC) countries: An expert consensus summary statement from the GCC vitamin D advisory board. Archives of osteoporosis.2020; 15, 1-8.‏
  42. Hantoosh H, Mahdi M, Imran B, Yahya A. Prevalence of vitamin D deficiency in Iraqi female at reproductive age. Med J Babylon.2019;16(2):119-122.‏
  43. Hussein I, Mansour A, Nwayyir H ,Almomin A, Alibrahim N, Alidrisi H, Alhamza A. Real-Life Data on Total Vitamin D3 (25-Hydroxyvitamin D) Concentrations in Basrah, Iraq. Biomedical & Pharmacology Journal.2021;14(4):2191-2198.‏
  44. Al Janaby S, Al Timimy, G. Prevalence of Vitamin D Deficiency of Females in Karbala, Iraq, 2017. Kerbala Jorunal of Medicine.2020;13(1)
  45. Sánchez‐Armendáriz K, García‐Gil A, Romero C, Contreras‐Ruiz J, Karam‐Orante, M, Balcazar‐Antonio D, Domínguez‐Cherit J. Oral vitamin D3 5000 IU/day as an adjuvant in the treatment of atopic dermatitis: a randomized control trial. International Journal of Dermatology.2018;57(12): 1516-1520.‏‏
  46. Uva L, Miguel D., Pinheiro C, Antunes J, Cruz D, Ferreira J, Filipe P. Mechanisms of action of topical corticosteroids in psoriasis. International journal of endocrinolog.2012:, 2012.‏
Statistics
Article View: 230
PDF Download: 146


Journal Management System. Powered by ejournalplus.com